Actinium clears path for fundraising and listing to advance alpha/MAb therapies

The Newark, New Jersey-based privately held company Actinium Pharmaceuticals, which is developing drugs combining cell-targeting antibodies with alpha-emitting radioisotopes to treat cancer, has secured approval from its shareholders to raise up to $25 million and seek a public listing.